Phase I Study of Patients With Advanced or Recurrent Malignancy
Phase I Study of Intraperitoneal PV701 in Patients With Advanced or Recurrent
Malignancy Largely Confined to the Peritoneal Cavity
Background:
PV701 may be able to kill tumor cells while leaving normal cells undamaged. This
is a Phase I trial to study the effectiveness of PV701 in treating patients who
have advanced or recurrent ovarian epithelial, fallopian tube, primary peritoneal,
colorectal, or other cancer within the peritoneal cavity.
Memorial Sloan-Kettering Cancer Center
Owen A. O'Connor, MD, PhD, Protocol Chair
Ph: 212-639-8889
Location/Contacts:
New York
New York
Memorial Sloan-Kettering Cancer Center
Leonard Bruce Saltz, MD
Ph: 212-639-2501
Owen A. O'Connor, MD, PhD
Ph: 212-639-8889
